A positive effect of intensification of the treatment with biosimilar insulin glargine on metabolic compensation: case report
Authors:
Lucia Kizeková
Authors place of work:
IV. interná klinika UNLP a LF UPJS Košice
Published in the journal:
Diab Obez 2020; 20(39): 63-65
Category:
Case studies
Zdroje
- [American Diabetes Association]. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd 2018. Diabetes Care 2018; 41(Suppl 1): S73-S85. Dostupné z DOI: <https://doi.org/10.2337/dc18-S008>>.
- Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Forum Diab 2018; 7(1): 47–68.
- Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced Hypoglycemia Risk with Insulin Glargine. Diabetes Care 2005; 28(4): 950–955. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.28.4.950>.
- Semglee. Dostupné z DOI: <https://www.ema.europa.eu/en/documents/product-information/semglee-epar-product-information_sk.pdf>.
Štítky
Diabetology ObesitologyČlánok vyšiel v časopise
Diabetes and obesity
Najčítanejšie v tomto čísle
- Diabetes mellitus and liver diseases
- Treatment with the new modified insulin glargine (Semglee) in a patient with type 1 diabetes mellitus: case report
- Non-alcoholic fatty liver disease from the point of view of diabetologist
- Comparison of the most recent guidelines for hyperglycemia management in patients with type 2 diabetes mellitus